BOARD MEMBER
Shingo Nakamura
Representative Director, Founder and
Chief Executive Officer
Shingo Nakamura founded Veritas In Silico and became Representative Director in 2016. He has a wide variety of hands-on experience in drug discovery research, interactions with regulatory authorities, business development, sales operations, and investment in biotech firms.
Prior to founding Veritas In Silico, Shingo served as Investing Director at INCJ, Ltd. in 2015-2017, Business Development Director at Catalent Pharma Solutions in 2011-2015, and Sales Department Manager at the Dow Chemical Company in 2011. Previously, he worked for Takeda Pharmaceutical Company Limited since 2003, where he ran an mRNA-targeted drug discovery project from 2004. He left the company in 2011 when the project was discontinued due to the company policy.
Shingo earned his Ph.D. degree (D.Eng.) in organic chemistry from the Graduate School of Engineering, Nagoya University, and passed Japan’s Class I Information Technology Engineer Examination in 2000. Then he joined the Breaker Laboratory, Yale University as a postdoctoral fellow, and conducted research on the molecular and cellular biology of nucleic acids.
Hiroaki Hagiwara
Director
Hiroaki Hagiwara joined Veritas In Silico in 2019, then he was appointed as General Manager of Administration in 2022, and Director and General Manager of Administration in 2024. He has over 30 years of work experience as an administrator in a wide range of industries and has completed two IPOs, including Veritas In Silico.
Before Veritas In Silico, Hiroaki first joined Hinoki Holdings in 2003, where he experienced IPO operations, and was engaged as the General Manager of the Accounting Department from 2009. Since 2014, he has worked for several companies aiming for IPOs until he joined Veritas In Silico. In those companies, he has held various positions such as General Manager of Administration, Executive Officer of Administration, and Director of Finance, overseeing the administrative divisions.
Isao Koda
Director
Isao Koda joined Veritas In Silico in 2018 as General Manager of Business Development, then was appointed as Director and General Manager of Business Development in 2024. He has more than 40 years of experience in the pharmaceutical industry, including approx. 15 years in the U.S., ranging from drug discovery research and clinical development to business development.
Before Veritas In Silico, Isao joined Merck in 2013 as Director, MRL BD&L and was responsible for new technology exploration within Japan and contract negotiations, including research collaborations, licenses, and M&A. Previously, he worked at the pharmaceutical division of Nissan Chemical from 2003 in charge of clinical development and business development, where he led many licensing negotiations including two licensing agreements with a U.S. company.
Isao earned his Ph.D. in Pharmaceutical Sciences from Osaka University Graduate School of Pharmaceutical Sciences in 1992.
Kinichiro Kominami
Director
Kinichiro Kominami, Representative Director and Chief Executive Officer of Tech & FinStrategy, Inc., was appointed as Director of Veritas In Silico in 2019. He provides consulting services to startups for preparing IPO as a director, supports major companies to branch out into new businesses, and gives support to venture capital firms and financial institutions.
Kinichiro founded Tech & FinStrategy in 2017. Prior to founding the company, he worked in the securities industry since 2001. Most recently, he conducted research on IPOs and coordinated the cooperation between industry and academia as Corporate Group Director of the Domestic Business Division, Mizuho Securities Co., Ltd. Before Mizuho Securities, he conducted research on IPOs in the Research Division of Nomura Research & Advisory Co., Ltd. (Nomura Securities Co., Ltd.) and invested in 24 biotech firms in the Investment Division, 12 of which have now been listed on the Tokyo Stock Exchange.
Kinichiro earned his Ph.D. degree (D. Sci.) from the Graduate School of Science, the University of Tokyo in 1994, and then worked at the Imperial Cancer Research Fund Laboratories (U.K.) as a postdoctoral fellow. He became an assistant at the Medical Institute of Bioregulation, Kyushu University (molecular biology) in 1998.
Sadao Suzuki
Audit & Supervisory Board Member
Sadao Suzuki was appointed as Audit & Supervisory Board Member of Veritas In Silico in 2019. He has firsthand experience in asset management at a life insurance company and a wealth of experience as an audit & supervisory board member.
Prior to joining Veritas In Silico, Sadao joined Asahi Mutual Life Insurance Company in 1976, where he became Financial Review Manager in 2002, and then he served as Audit & Supervisory Board Member since 2008 at Asahi Mutual Life Insurance Company, TBK Co., Ltd., and Shin Corporation.
Sadao earned a bachelor’s degree in sociology from the Faculty of Letters, the University of Tokyo in 1976.
Minoru Hirooka
Audit & Supervisory Board Member
Minoru Hirooka, Head of Hirooka Certified Public Accountant Office, was appointed as Audit & Supervisory Board Member of Veritas In Silico in 2019. He is a certified public accountant and licensed tax accountant, not only providing services such as accounting audits, tax advising, business valuation, and listing support, but also enhancing governance systems as a non-executive officer of listed companies.
Minoru set up Hirooka Certified Public Accountant Office in 2009. He engaged in accounting audit, listing support, and other services at a major auditing firm from 1997 to 2008.
Minoru earned a bachelor’s degree in Business and Commerce from Keio University in 1995.
Minako Wakabayashi
Audit & Supervisory Board Member
Minako Wakabayashi, a lawyer and partner in Orrick’s Tokyo office (Foreign Law Joint Enterprise), was appointed as Audit & Supervisory Board Member of Veritas In Silico in 2022. She is a member of Orrick’s Energy & Infrastructure Group and has been accelerating the growth of renewable energy markets in Japan. She currently serves as Auditor of the Japan Wind Power Association (JWPA) and has eight years of experience as a member of the Tokyo Metropolitan Government Supervising Committee for Public Bidding.
Minako joined Orrick in 2004. Prior to that, she served as a public prosecutor since 1998 at Tokyo, Saitama, and Mito District Public Prosecutor’s Offices, after completing the course at the Legal Training and Research Institute, the Supreme Court of Japan.
Minako earned a bachelor’s degree in Economics from Keio University in 1996, and a master’s degree in law (LLM) from the University of Chicago Law School in 2004.
